By Patrick Crutcher
There are several news events that investors should be looking out for over the next 1-2 quarters. Depomed hopes to conclude the investigation into the 500mg Glumetza recall and they’re currently projecting resupply in December or early 2011. Depomed is in discussions with several potential partners for the ex-US rights to DM-1796. They expect positive results in early 2011 for DM-1992, which they have had strong outside interest in. Depomed hopes to outlicense both DM-1992 and DM-3458 to partners in 2011. Carl Pelzel, CEO of Depomed, has also said that investors could potentially expect to see more Acuform XR metformin transactions -- similar to the Janssen and Merck (NYSE:MRK) deals. They expect to end 2010 with more than $70 million in cash and no debt.
Traders have already begun hedging their bets on FDA approval. Their March 2011 options have the most outstanding interest with 4700 $7.50 calls and 3300 puts at $5. Technically, the money flow index is at all-time highs and speaks to the demand for shares.
Disclosure: Long DEPO